A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.

J Hematol Oncol · 2013 · PMC3585853 · PMID 23414938

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Conclusion In summary, the results of this randomized, double-blind, Phase 2 study showed that prasugrel inhibited platelet function, decreased biomarkers of platelet activation, and showed a trend toward decreased pain by several measures without serious hemorrhagic adverse events.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

However, these decreases did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.